Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model
Alzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleoti...
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | مقال |
| اللغة: | English |
| منشور في: |
Frontiers Media S.A.
2022-09-01
|
| سلاسل: | Frontiers in Aging Neuroscience |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://www.frontiersin.org/articles/10.3389/fnagi.2022.993615/full |
| _version_ | 1828105144602984448 |
|---|---|
| author | Xixia Chu Yujun Hou Yujun Hou Qiong Meng Deborah L. Croteau Deborah L. Croteau Yong Wei Supriyo De Kevin G. Becker Vilhelm A. Bohr |
| author_facet | Xixia Chu Yujun Hou Yujun Hou Qiong Meng Deborah L. Croteau Deborah L. Croteau Yong Wei Supriyo De Kevin G. Becker Vilhelm A. Bohr |
| author_sort | Xixia Chu |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide riboside (NR), reduced the brain features of AD, including neuroinflammation, deoxyribonucleic acid (DNA) damage, synaptic dysfunction, and cognitive impairment. However, the impact of NR administration on the intestinal microbiota of AD remains unknown. In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice. Compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower and the microbiota composition and enterotype were significantly different. Moreover, there were gender differences in gut microbiome between female and male AD mice. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice. This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD. |
| first_indexed | 2024-04-11T09:58:53Z |
| format | Article |
| id | doaj.art-dbd0f437e9bb44e8889e1b83f90a8e14 |
| institution | Directory Open Access Journal |
| issn | 1663-4365 |
| language | English |
| last_indexed | 2024-04-11T09:58:53Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Aging Neuroscience |
| spelling | doaj.art-dbd0f437e9bb44e8889e1b83f90a8e142022-12-22T04:30:29ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652022-09-011410.3389/fnagi.2022.993615993615Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse modelXixia Chu0Yujun Hou1Yujun Hou2Qiong Meng3Deborah L. Croteau4Deborah L. Croteau5Yong Wei6Supriyo De7Kevin G. Becker8Vilhelm A. Bohr9DNA Repair Section, National Institute on Aging, Baltimore, MD, United StatesDNA Repair Section, National Institute on Aging, Baltimore, MD, United StatesInstitute for Regenerative Medicine, Shanghai East Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, ChinaLaboratory of Genetics and Genomics, National Institute on Aging, Baltimore, MD, United StatesDNA Repair Section, National Institute on Aging, Baltimore, MD, United StatesLaboratory of Genetics and Genomics, National Institute on Aging, Baltimore, MD, United StatesDNA Repair Section, National Institute on Aging, Baltimore, MD, United StatesLaboratory of Genetics and Genomics, National Institute on Aging, Baltimore, MD, United StatesLaboratory of Genetics and Genomics, National Institute on Aging, Baltimore, MD, United StatesDNA Repair Section, National Institute on Aging, Baltimore, MD, United StatesAlzheimer’s disease (AD) is the most common neurodegenerative disease. Growing evidence suggests an important role for gut dysbiosis and gut microbiota-host interactions in aging and neurodegeneration. Our previous works have demonstrated that supplementation with the nicotinamide adenine dinucleotide (NAD+) precursor, nicotinamide riboside (NR), reduced the brain features of AD, including neuroinflammation, deoxyribonucleic acid (DNA) damage, synaptic dysfunction, and cognitive impairment. However, the impact of NR administration on the intestinal microbiota of AD remains unknown. In this study, we investigated the relationship between gut microbiota and NR treatment in APP/PS1 transgenic (AD) mice. Compared with wild type (WT) mice, the gut microbiota diversity in AD mice was lower and the microbiota composition and enterotype were significantly different. Moreover, there were gender differences in gut microbiome between female and male AD mice. After supplementation with NR for 8 weeks, the decreased diversity and perturbated microbial compositions were normalized in AD mice. This included the species Oscillospira, Butyricicoccus, Desulfovibrio, Bifidobacterium, Olsenella, Adlercreutzia, Bacteroides, Akkermansia, and Lactobacillus. Our results indicate an interplay between NR and host-microbiota in APP/PS1 mice, suggesting that the effect of NR on gut dysbiosis may be an important component in its therapeutic functions in AD.https://www.frontiersin.org/articles/10.3389/fnagi.2022.993615/fullAlzheimer’s diseasenicotinamide ribosidegut microbiomeAPP/PS1 transgenic miceneuroinflammationaging |
| spellingShingle | Xixia Chu Yujun Hou Yujun Hou Qiong Meng Deborah L. Croteau Deborah L. Croteau Yong Wei Supriyo De Kevin G. Becker Vilhelm A. Bohr Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model Frontiers in Aging Neuroscience Alzheimer’s disease nicotinamide riboside gut microbiome APP/PS1 transgenic mice neuroinflammation aging |
| title | Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model |
| title_full | Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model |
| title_fullStr | Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model |
| title_full_unstemmed | Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model |
| title_short | Nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in Alzheimer’s mouse model |
| title_sort | nicotinamide adenine dinucleotide supplementation drives gut microbiota variation in alzheimer s mouse model |
| topic | Alzheimer’s disease nicotinamide riboside gut microbiome APP/PS1 transgenic mice neuroinflammation aging |
| url | https://www.frontiersin.org/articles/10.3389/fnagi.2022.993615/full |
| work_keys_str_mv | AT xixiachu nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT yujunhou nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT yujunhou nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT qiongmeng nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT deborahlcroteau nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT deborahlcroteau nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT yongwei nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT supriyode nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT kevingbecker nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel AT vilhelmabohr nicotinamideadeninedinucleotidesupplementationdrivesgutmicrobiotavariationinalzheimersmousemodel |